nodes	percent_of_prediction	percent_of_DWPC	metapath
Arsenic trioxide—ABCC2—bile duct—bile duct cancer	0.0414	0.188	CbGeAlD
Arsenic trioxide—ABCC2—bile—bile duct cancer	0.0318	0.145	CbGeAlD
Arsenic trioxide—CCND1—pancreas—bile duct cancer	0.0122	0.0556	CbGeAlD
Arsenic trioxide—MAPK1—pancreas—bile duct cancer	0.0103	0.0468	CbGeAlD
Arsenic trioxide—TXNRD1—pancreas—bile duct cancer	0.00957	0.0436	CbGeAlD
Arsenic trioxide—MAPK3—pancreas—bile duct cancer	0.0091	0.0414	CbGeAlD
Arsenic trioxide—AKT1—pancreas—bile duct cancer	0.00858	0.0391	CbGeAlD
Arsenic trioxide—CCND1—liver—bile duct cancer	0.00777	0.0354	CbGeAlD
Arsenic trioxide—JUN—pancreas—bile duct cancer	0.00747	0.034	CbGeAlD
Arsenic trioxide—MAPK1—liver—bile duct cancer	0.00654	0.0298	CbGeAlD
Arsenic trioxide—TXNRD1—liver—bile duct cancer	0.00609	0.0277	CbGeAlD
Arsenic trioxide—CCND1—lymph node—bile duct cancer	0.00595	0.0271	CbGeAlD
Arsenic trioxide—MAPK3—liver—bile duct cancer	0.00579	0.0264	CbGeAlD
Arsenic trioxide—AKT1—liver—bile duct cancer	0.00546	0.0249	CbGeAlD
Arsenic trioxide—MAPK1—lymph node—bile duct cancer	0.00502	0.0228	CbGeAlD
Arsenic trioxide—JUN—liver—bile duct cancer	0.00475	0.0216	CbGeAlD
Arsenic trioxide—IKBKB—liver—bile duct cancer	0.00473	0.0215	CbGeAlD
Arsenic trioxide—TXNRD1—lymph node—bile duct cancer	0.00467	0.0213	CbGeAlD
Arsenic trioxide—MAPK3—lymph node—bile duct cancer	0.00444	0.0202	CbGeAlD
Arsenic trioxide—AKT1—lymph node—bile duct cancer	0.00419	0.0191	CbGeAlD
Arsenic trioxide—JUN—lymph node—bile duct cancer	0.00365	0.0166	CbGeAlD
Arsenic trioxide—IKBKB—lymph node—bile duct cancer	0.00363	0.0165	CbGeAlD
Arsenic trioxide—ABCC2—liver—bile duct cancer	0.00259	0.0118	CbGeAlD
Arsenic trioxide—CYP1B1—liver—bile duct cancer	0.00253	0.0115	CbGeAlD
Arsenic trioxide—ABCC2—lymph node—bile duct cancer	0.00198	0.00903	CbGeAlD
Arsenic trioxide—CYP1B1—lymph node—bile duct cancer	0.00194	0.00884	CbGeAlD
Arsenic trioxide—CYP1A1—liver—bile duct cancer	0.00179	0.00815	CbGeAlD
Arsenic trioxide—ABCB1—pancreas—bile duct cancer	0.00146	0.00666	CbGeAlD
Arsenic trioxide—CYP1A1—lymph node—bile duct cancer	0.00137	0.00625	CbGeAlD
Arsenic trioxide—CYP3A4—liver—bile duct cancer	0.00131	0.00598	CbGeAlD
Arsenic trioxide—ABCB1—liver—bile duct cancer	0.000931	0.00424	CbGeAlD
Arsenic trioxide—ABCB1—lymph node—bile duct cancer	0.000714	0.00325	CbGeAlD
Arsenic trioxide—MAPK1—Developmental Biology—MMP9—bile duct cancer	8.19e-05	0.000105	CbGpPWpGaD
Arsenic trioxide—IKBKB—Immune System—HGF—bile duct cancer	8.15e-05	0.000104	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—SMAD4—bile duct cancer	8.1e-05	0.000104	CbGpPWpGaD
Arsenic trioxide—IKBKB—Innate Immune System—ERBB2—bile duct cancer	8.07e-05	0.000103	CbGpPWpGaD
Arsenic trioxide—CYP1B1—Metabolism—SLC5A5—bile duct cancer	8.01e-05	0.000103	CbGpPWpGaD
Arsenic trioxide—MAPK1—Cytokine Signaling in Immune system—IL6—bile duct cancer	8.01e-05	0.000103	CbGpPWpGaD
Arsenic trioxide—IKBKB—Cytokine Signaling in Immune system—HRAS—bile duct cancer	8.01e-05	0.000103	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling by NGF—IL6—bile duct cancer	7.88e-05	0.000101	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling by NGF—HRAS—bile duct cancer	7.87e-05	0.000101	CbGpPWpGaD
Arsenic trioxide—AKT1—Developmental Biology—NRAS—bile duct cancer	7.87e-05	0.000101	CbGpPWpGaD
Arsenic trioxide—MAPK3—Axon guidance—HRAS—bile duct cancer	7.83e-05	0.0001	CbGpPWpGaD
Arsenic trioxide—IKBKB—Adaptive Immune System—ERBB2—bile duct cancer	7.75e-05	9.93e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Hemostasis—NRAS—bile duct cancer	7.72e-05	9.9e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Cytokine Signaling in Immune system—IL6—bile duct cancer	7.66e-05	9.82e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Developmental Biology—NRAS—bile duct cancer	7.63e-05	9.78e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling by NGF—IL6—bile duct cancer	7.54e-05	9.66e-05	CbGpPWpGaD
Arsenic trioxide—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	7.51e-05	9.63e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—ERBB2—bile duct cancer	7.49e-05	9.6e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Metabolism—GNAS—bile duct cancer	7.49e-05	9.6e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Axon guidance—IL6—bile duct cancer	7.49e-05	9.6e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Hemostasis—NRAS—bile duct cancer	7.49e-05	9.6e-05	CbGpPWpGaD
Arsenic trioxide—CYP1A1—Metabolism—IDH1—bile duct cancer	7.48e-05	9.59e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Axon guidance—HRAS—bile duct cancer	7.45e-05	9.54e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Developmental Biology—TGFB1—bile duct cancer	7.31e-05	9.37e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Developmental Biology—NRAS—bile duct cancer	7.26e-05	9.31e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Innate Immune System—NRAS—bile duct cancer	7.24e-05	9.27e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Hemostasis—TGFB1—bile duct cancer	7.17e-05	9.2e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Developmental Biology—EGFR—bile duct cancer	7.17e-05	9.19e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Axon guidance—IL6—bile duct cancer	7.13e-05	9.13e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Hemostasis—NRAS—bile duct cancer	7.13e-05	9.13e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Developmental Biology—TGFB1—bile duct cancer	7.09e-05	9.09e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Hemostasis—TGFB1—bile duct cancer	6.96e-05	8.92e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Developmental Biology—EGFR—bile duct cancer	6.96e-05	8.91e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Innate Immune System—NRAS—bile duct cancer	6.95e-05	8.91e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Metabolism—IDH2—bile duct cancer	6.95e-05	8.91e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Developmental Biology—KRAS—bile duct cancer	6.77e-05	8.68e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—TGFBR2—bile duct cancer	6.76e-05	8.66e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Developmental Biology—TGFB1—bile duct cancer	6.75e-05	8.65e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Innate Immune System—NRAS—bile duct cancer	6.74e-05	8.64e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Adaptive Immune System—NRAS—bile duct cancer	6.68e-05	8.55e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Hemostasis—KRAS—bile duct cancer	6.65e-05	8.52e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Hemostasis—TGFB1—bile duct cancer	6.62e-05	8.49e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Developmental Biology—EGFR—bile duct cancer	6.62e-05	8.48e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Innate Immune System—EGFR—bile duct cancer	6.59e-05	8.45e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Developmental Biology—KRAS—bile duct cancer	6.57e-05	8.42e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	6.54e-05	8.38e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—NOS2—bile duct cancer	6.53e-05	8.37e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—GNAS—bile duct cancer	6.52e-05	8.36e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—TGFBR2—bile duct cancer	6.49e-05	8.32e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Hemostasis—KRAS—bile duct cancer	6.45e-05	8.26e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—MMP9—bile duct cancer	6.43e-05	8.24e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Innate Immune System—NRAS—bile duct cancer	6.42e-05	8.22e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—SMAD4—bile duct cancer	6.4e-05	8.2e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	6.4e-05	8.2e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—NOS2—bile duct cancer	6.34e-05	8.12e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Innate Immune System—EGFR—bile duct cancer	6.33e-05	8.12e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—TGFBR2—bile duct cancer	6.3e-05	8.07e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	6.27e-05	8.04e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—GNAS—bile duct cancer	6.26e-05	8.03e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Developmental Biology—KRAS—bile duct cancer	6.25e-05	8.01e-05	CbGpPWpGaD
Arsenic trioxide—CYP1B1—Metabolism—GNAS—bile duct cancer	6.23e-05	7.98e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Innate Immune System—KRAS—bile duct cancer	6.23e-05	7.98e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—SMAD4—bile duct cancer	6.15e-05	7.88e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Innate Immune System—EGFR—bile duct cancer	6.14e-05	7.87e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Innate Immune System—NRAS—bile duct cancer	6.14e-05	7.87e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Hemostasis—KRAS—bile duct cancer	6.13e-05	7.86e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Adaptive Immune System—EGFR—bile duct cancer	6.08e-05	7.79e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—GNAS—bile duct cancer	6.08e-05	7.79e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—NOS2—bile duct cancer	6.03e-05	7.73e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—TGFBR2—bile duct cancer	5.99e-05	7.68e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Innate Immune System—KRAS—bile duct cancer	5.98e-05	7.67e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Metabolism—IDH1—bile duct cancer	5.98e-05	7.66e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—SMAD4—bile duct cancer	5.96e-05	7.64e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	5.92e-05	7.59e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Hemostasis—TP53—bile duct cancer	5.91e-05	7.57e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Adaptive Immune System—NRAS—bile duct cancer	5.89e-05	7.55e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Innate Immune System—EGFR—bile duct cancer	5.84e-05	7.49e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Innate Immune System—KRAS—bile duct cancer	5.8e-05	7.44e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—GNAS—bile duct cancer	5.78e-05	7.41e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Developmental Biology—HRAS—bile duct cancer	5.76e-05	7.38e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Adaptive Immune System—KRAS—bile duct cancer	5.75e-05	7.36e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—TGFBR2—bile duct cancer	5.73e-05	7.35e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Hemostasis—TP53—bile duct cancer	5.73e-05	7.34e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—NRAS—bile duct cancer	5.7e-05	7.31e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—SMAD4—bile duct cancer	5.67e-05	7.27e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Hemostasis—HRAS—bile duct cancer	5.65e-05	7.24e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Innate Immune System—EGFR—bile duct cancer	5.59e-05	7.17e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Developmental Biology—HRAS—bile duct cancer	5.59e-05	7.16e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Immune System—ERBB2—bile duct cancer	5.54e-05	7.1e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—GNAS—bile duct cancer	5.53e-05	7.09e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Innate Immune System—KRAS—bile duct cancer	5.52e-05	7.08e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Developmental Biology—IL6—bile duct cancer	5.51e-05	7.06e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Hemostasis—HRAS—bile duct cancer	5.48e-05	7.02e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Hemostasis—TP53—bile duct cancer	5.45e-05	6.99e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—SMAD4—bile duct cancer	5.43e-05	6.96e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Cell Cycle—TP53—bile duct cancer	5.41e-05	6.93e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Adaptive Immune System—EGFR—bile duct cancer	5.37e-05	6.88e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Developmental Biology—IL6—bile duct cancer	5.35e-05	6.85e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Immune System—ERBB2—bile duct cancer	5.32e-05	6.82e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Developmental Biology—HRAS—bile duct cancer	5.31e-05	6.81e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—TGFB1—bile duct cancer	5.3e-05	6.79e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Innate Immune System—HRAS—bile duct cancer	5.29e-05	6.78e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Innate Immune System—KRAS—bile duct cancer	5.28e-05	6.77e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	5.27e-05	6.75e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Hemostasis—HRAS—bile duct cancer	5.21e-05	6.68e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—EGFR—bile duct cancer	5.19e-05	6.66e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Immune System—ERBB2—bile duct cancer	5.16e-05	6.62e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Cell Cycle—TP53—bile duct cancer	5.14e-05	6.59e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Developmental Biology—IL6—bile duct cancer	5.09e-05	6.52e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Innate Immune System—HRAS—bile duct cancer	5.09e-05	6.52e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Adaptive Immune System—KRAS—bile duct cancer	5.07e-05	6.5e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Innate Immune System—IL6—bile duct cancer	5.07e-05	6.49e-05	CbGpPWpGaD
Arsenic trioxide—CYP1A1—Metabolism—SLC5A5—bile duct cancer	4.94e-05	6.33e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Innate Immune System—HRAS—bile duct cancer	4.93e-05	6.32e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—ERBB2—bile duct cancer	4.91e-05	6.3e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Immune System—ERBB2—bile duct cancer	4.91e-05	6.29e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—KRAS—bile duct cancer	4.91e-05	6.29e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Adaptive Immune System—HRAS—bile duct cancer	4.88e-05	6.26e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Innate Immune System—IL6—bile duct cancer	4.87e-05	6.24e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—PTGS2—bile duct cancer	4.8e-05	6.16e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—ERBB2—bile duct cancer	4.77e-05	6.11e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Innate Immune System—IL6—bile duct cancer	4.72e-05	6.05e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Immune System—ERBB2—bile duct cancer	4.7e-05	6.02e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Innate Immune System—HRAS—bile duct cancer	4.69e-05	6.01e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—PTGS2—bile duct cancer	4.66e-05	5.97e-05	CbGpPWpGaD
Arsenic trioxide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	4.63e-05	5.93e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—ERBB2—bile duct cancer	4.53e-05	5.81e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Innate Immune System—IL6—bile duct cancer	4.49e-05	5.76e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Innate Immune System—HRAS—bile duct cancer	4.49e-05	5.75e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—PTGS2—bile duct cancer	4.43e-05	5.68e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling by GPCR—NRAS—bile duct cancer	4.43e-05	5.68e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—TP53—bile duct cancer	4.36e-05	5.59e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Adaptive Immune System—HRAS—bile duct cancer	4.31e-05	5.53e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling by GPCR—NRAS—bile duct cancer	4.3e-05	5.51e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Innate Immune System—IL6—bile duct cancer	4.3e-05	5.51e-05	CbGpPWpGaD
Arsenic trioxide—CYP3A4—Metabolism—IDH2—bile duct cancer	4.28e-05	5.49e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Immune System—NRAS—bile duct cancer	4.21e-05	5.4e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—HRAS—bile duct cancer	4.17e-05	5.35e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling by GPCR—NRAS—bile duct cancer	4.09e-05	5.24e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Immune System—NRAS—bile duct cancer	4.05e-05	5.19e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling by GPCR—EGFR—bile duct cancer	4.04e-05	5.17e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Metabolism—PTGS2—bile duct cancer	4.02e-05	5.16e-05	CbGpPWpGaD
Arsenic trioxide—CCND1—Signaling Pathways—IL6—bile duct cancer	3.99e-05	5.12e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Metabolism—SLC5A5—bile duct cancer	3.94e-05	5.05e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Immune System—NRAS—bile duct cancer	3.93e-05	5.03e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling by GPCR—EGFR—bile duct cancer	3.92e-05	5.02e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Immune System—EGFR—bile duct cancer	3.84e-05	4.92e-05	CbGpPWpGaD
Arsenic trioxide—CYP1A1—Metabolism—GNAS—bile duct cancer	3.84e-05	4.92e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling by GPCR—KRAS—bile duct cancer	3.81e-05	4.89e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—NRAS—bile duct cancer	3.74e-05	4.79e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Immune System—NRAS—bile duct cancer	3.74e-05	4.79e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling by GPCR—EGFR—bile duct cancer	3.73e-05	4.78e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling by GPCR—KRAS—bile duct cancer	3.7e-05	4.74e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Immune System—EGFR—bile duct cancer	3.69e-05	4.73e-05	CbGpPWpGaD
Arsenic trioxide—CYP3A4—Metabolism—IDH1—bile duct cancer	3.68e-05	4.72e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Immune System—KRAS—bile duct cancer	3.63e-05	4.65e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—NRAS—bile duct cancer	3.63e-05	4.65e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—ERBB2—bile duct cancer	3.58e-05	4.59e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Immune System—EGFR—bile duct cancer	3.58e-05	4.59e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Immune System—NRAS—bile duct cancer	3.57e-05	4.58e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling by GPCR—KRAS—bile duct cancer	3.52e-05	4.51e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Immune System—KRAS—bile duct cancer	3.48e-05	4.47e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—TGFB1—bile duct cancer	3.47e-05	4.45e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—NRAS—bile duct cancer	3.45e-05	4.42e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—ERBB2—bile duct cancer	3.44e-05	4.41e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—EGFR—bile duct cancer	3.41e-05	4.36e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Immune System—EGFR—bile duct cancer	3.4e-05	4.36e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Immune System—KRAS—bile duct cancer	3.38e-05	4.33e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—TGFB1—bile duct cancer	3.37e-05	4.32e-05	CbGpPWpGaD
Arsenic trioxide—CYP1B1—Metabolism—PTGS2—bile duct cancer	3.34e-05	4.29e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—ERBB2—bile duct cancer	3.34e-05	4.28e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—EGFR—bile duct cancer	3.3e-05	4.23e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Immune System—EGFR—bile duct cancer	3.26e-05	4.17e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling by GPCR—HRAS—bile duct cancer	3.24e-05	4.15e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—KRAS—bile duct cancer	3.22e-05	4.12e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Immune System—KRAS—bile duct cancer	3.22e-05	4.12e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—TGFB1—bile duct cancer	3.21e-05	4.11e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—ERBB2—bile duct cancer	3.18e-05	4.07e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling by GPCR—HRAS—bile duct cancer	3.14e-05	4.03e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—EGFR—bile duct cancer	3.14e-05	4.03e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—KRAS—bile duct cancer	3.12e-05	4e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling by GPCR—IL6—bile duct cancer	3.1e-05	3.98e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Immune System—HRAS—bile duct cancer	3.08e-05	3.95e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Immune System—KRAS—bile duct cancer	3.08e-05	3.94e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—MMP9—bile duct cancer	3.07e-05	3.94e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Metabolism—GNAS—bile duct cancer	3.06e-05	3.93e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—ERBB2—bile duct cancer	3.04e-05	3.89e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling by GPCR—IL6—bile duct cancer	3.01e-05	3.86e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling by GPCR—HRAS—bile duct cancer	2.99e-05	3.83e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—KRAS—bile duct cancer	2.97e-05	3.81e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Immune System—HRAS—bile duct cancer	2.96e-05	3.8e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—MMP9—bile duct cancer	2.95e-05	3.78e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Immune System—IL6—bile duct cancer	2.95e-05	3.78e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Immune System—HRAS—bile duct cancer	2.87e-05	3.68e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling by GPCR—IL6—bile duct cancer	2.86e-05	3.67e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—MMP9—bile duct cancer	2.86e-05	3.67e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Immune System—IL6—bile duct cancer	2.84e-05	3.63e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Immune System—IL6—bile duct cancer	2.75e-05	3.52e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—HRAS—bile duct cancer	2.73e-05	3.5e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Immune System—HRAS—bile duct cancer	2.73e-05	3.5e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—NRAS—bile duct cancer	2.72e-05	3.49e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—MMP9—bile duct cancer	2.72e-05	3.49e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—HRAS—bile duct cancer	2.65e-05	3.4e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—NRAS—bile duct cancer	2.62e-05	3.35e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Disease—IL6—bile duct cancer	2.62e-05	3.35e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Immune System—IL6—bile duct cancer	2.62e-05	3.35e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Immune System—HRAS—bile duct cancer	2.62e-05	3.35e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—MMP9—bile duct cancer	2.61e-05	3.34e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—NRAS—bile duct cancer	2.54e-05	3.25e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Disease—IL6—bile duct cancer	2.54e-05	3.25e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—TGFB1—bile duct cancer	2.53e-05	3.24e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—HRAS—bile duct cancer	2.52e-05	3.23e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Immune System—IL6—bile duct cancer	2.5e-05	3.21e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—EGFR—bile duct cancer	2.48e-05	3.18e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—TGFB1—bile duct cancer	2.43e-05	3.12e-05	CbGpPWpGaD
Arsenic trioxide—CYP3A4—Metabolism—SLC5A5—bile duct cancer	2.43e-05	3.11e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—NRAS—bile duct cancer	2.42e-05	3.1e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Disease—IL6—bile duct cancer	2.42e-05	3.1e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—EGFR—bile duct cancer	2.38e-05	3.06e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—TGFB1—bile duct cancer	2.36e-05	3.02e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—KRAS—bile duct cancer	2.35e-05	3.01e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—EGFR—bile duct cancer	2.31e-05	2.96e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—NRAS—bile duct cancer	2.31e-05	2.96e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—KRAS—bile duct cancer	2.25e-05	2.89e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—TGFB1—bile duct cancer	2.24e-05	2.88e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—EGFR—bile duct cancer	2.2e-05	2.82e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—KRAS—bile duct cancer	2.19e-05	2.8e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—TGFB1—bile duct cancer	2.15e-05	2.75e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—EGFR—bile duct cancer	2.11e-05	2.7e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—TP53—bile duct cancer	2.08e-05	2.67e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—KRAS—bile duct cancer	2.08e-05	2.66e-05	CbGpPWpGaD
Arsenic trioxide—CYP1A1—Metabolism—PTGS2—bile duct cancer	2.06e-05	2.64e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—TP53—bile duct cancer	2e-05	2.57e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—HRAS—bile duct cancer	1.99e-05	2.55e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—KRAS—bile duct cancer	1.99e-05	2.55e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—TP53—bile duct cancer	1.94e-05	2.49e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—HRAS—bile duct cancer	1.92e-05	2.45e-05	CbGpPWpGaD
Arsenic trioxide—JUN—Signaling Pathways—IL6—bile duct cancer	1.91e-05	2.45e-05	CbGpPWpGaD
Arsenic trioxide—CYP3A4—Metabolism—GNAS—bile duct cancer	1.89e-05	2.42e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—HRAS—bile duct cancer	1.86e-05	2.38e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—TP53—bile duct cancer	1.85e-05	2.37e-05	CbGpPWpGaD
Arsenic trioxide—AKT1—Signaling Pathways—IL6—bile duct cancer	1.83e-05	2.35e-05	CbGpPWpGaD
Arsenic trioxide—MAPK3—Signaling Pathways—IL6—bile duct cancer	1.78e-05	2.28e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—TP53—bile duct cancer	1.77e-05	2.27e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—HRAS—bile duct cancer	1.77e-05	2.27e-05	CbGpPWpGaD
Arsenic trioxide—MAPK1—Signaling Pathways—IL6—bile duct cancer	1.69e-05	2.17e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—HRAS—bile duct cancer	1.69e-05	2.17e-05	CbGpPWpGaD
Arsenic trioxide—ABCB1—Metabolism—PTGS2—bile duct cancer	1.65e-05	2.11e-05	CbGpPWpGaD
Arsenic trioxide—IKBKB—Signaling Pathways—IL6—bile duct cancer	1.62e-05	2.07e-05	CbGpPWpGaD
Arsenic trioxide—CYP3A4—Metabolism—PTGS2—bile duct cancer	1.01e-05	1.3e-05	CbGpPWpGaD
